Thaker, S. K., Dugan, A., Jariwala, U., Yilma, B., Weitz, M., Fragkogianni, S., Alkassis, S., Lipsyc-Sharf, M., LeVee, A. A., Yuan, Y., Meric-Bernstam, F., Rugo, H. S., O'Shaughnessy, J., Rimawi, M., Schiff, R., Elashoff, D., Mcdermott, M., Cummings, A. L., Mercer, J., Bardia, A. (2026). Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1030